Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: Pilot study in patients with hepatocellular carcinoma

  • Authors:
    • D. L. Morris
    • J.-L. Jourdan
    • I. Finlay
    • T. Gruenberger
    • M. P. The
    • M. H. Pourgholami
  • View Affiliations

  • Published online on: October 1, 2002     https://doi.org/10.3892/ijo.21.4.901
  • Pages: 901-906
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

1,25-dihydroxycholecalciferol [1,25-(OH)2 D3] has been shown to have antiproliferative effects in a wide variety of cancer cell lines. In vivo studies, although often limited by the development of hypercalcemia, have also shown the potential usefulness of 1,25-(OH)2 D3 in inhibiting tumor growth. The potential usefulness of the drug has been hampered by the development of hypercalcemia. This pilot clinical study was designed to evaluate the preclinical results that have shown, locoregional administration of 1,25-(OH)2 D3 in lipiodol can prevent the development of hypercalcemia. Eight patients with refractory HCC were given a single intrahepatic arterial dose (50, 75 or 100 μg) of 1,25-(OH)2 D3 dissolved in 5 ml of lipiodol. Following this, for 4 weeks serum calcium, 1,25-(OH)2 D3, α-fetoprotein and a range of biochemical indices were monitored. While, in 3 patients the calcium levels exceeded the normal range, even at these extremely high doses, non of the patients developed grade 3 hypercalcemia. 1,25-(OH)2 D3 administration also led to transient stabilization of serum α-fetoprotein in these patients. The data obtained support the hypothesis that, in patients with HCC, locoregional delivery of 1,25-(OH)2 D3 in lipiodol can allow administration of supra-pharmacological doses of the drug without the development of hypercalcemia.

Related Articles

Journal Cover

October 2002
Volume 21 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Morris, D.L., Jourdan, J., Finlay, I., Gruenberger, T., The, M.P., & Pourgholami, M.H. (2002). Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: Pilot study in patients with hepatocellular carcinoma. International Journal of Oncology, 21, 901-906. https://doi.org/10.3892/ijo.21.4.901
MLA
Morris, D. L., Jourdan, J., Finlay, I., Gruenberger, T., The, M. P., Pourgholami, M. H."Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: Pilot study in patients with hepatocellular carcinoma". International Journal of Oncology 21.4 (2002): 901-906.
Chicago
Morris, D. L., Jourdan, J., Finlay, I., Gruenberger, T., The, M. P., Pourgholami, M. H."Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: Pilot study in patients with hepatocellular carcinoma". International Journal of Oncology 21, no. 4 (2002): 901-906. https://doi.org/10.3892/ijo.21.4.901